- Home
- GVH vs INAB Comparison
GVH vs INAB Comparison
Compare GVH & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GVH
- INAB
- Stock Information
- Founded
- GVH 2016
- INAB 2016
- Country
- GVH Australia
- INAB United States
- Employees
- GVH N/A
- INAB N/A
- Industry
- GVH
- INAB Biotechnology: Pharmaceutical Preparations
- Sector
- GVH
- INAB Health Care
- Exchange
- GVH Nasdaq
- INAB Nasdaq
- Market Cap
- GVH 21.3M
- INAB 14.5M
- IPO Year
- GVH 2023
- INAB 2021
- Fundamental
- Price
- GVH $0.13
- INAB $2.09
- Analyst Decision
- GVH
- INAB Strong Buy
- Analyst Count
- GVH 0
- INAB 2
- Target Price
- GVH N/A
- INAB $108.00
- AVG Volume (30 Days)
- GVH 47.8M
- INAB 385.7K
- Earning Date
- GVH 02-12-2025
- INAB 08-07-2025
- Dividend Yield
- GVH N/A
- INAB N/A
- EPS Growth
- GVH 12.04
- INAB N/A
- EPS
- GVH 0.09
- INAB N/A
- Revenue
- GVH $16,540,178.00
- INAB N/A
- Revenue This Year
- GVH N/A
- INAB N/A
- Revenue Next Year
- GVH N/A
- INAB N/A
- P/E Ratio
- GVH $1.45
- INAB N/A
- Revenue Growth
- GVH N/A
- INAB N/A
- 52 Week Low
- GVH $0.11
- INAB $2.06
- 52 Week High
- GVH $1.82
- INAB $27.60
- Technical
- Relative Strength Index (RSI)
- GVH 22.26
- INAB 27.49
- Support Level
- GVH $1.33
- INAB $2.06
- Resistance Level
- GVH $1.54
- INAB $2.31
- Average True Range (ATR)
- GVH 0.14
- INAB 0.31
- MACD
- GVH -0.14
- INAB -0.00
- Stochastic Oscillator
- GVH 0.99
- INAB 4.74
About GVH Globavend Holdings Limited
Globavend Holdings Ltd is an e-commerce logistics provider, it provides integrated cross-border logistics services from Hong Kong to Australia and New Zealand, where it provides customers with a one-stop solution from parcel consolidation to air freight forwarding, customs clearance, on-carriage parcel transportation and delivery. It operates in logistics and freight forwarding industry, which involves the provision of services such as freight transport, freight forwarding, warehouse management, and distribution.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.